Spark Therapeutics: Earnings Update For This Core Biotech Holding


My last "buy the dip" piece was followed by an all-out implosion . An ex-US partnership inked with Novartis strengthened the bullish thesis and the firm appears increasingly prepared for its US launch.



from Biotech News